Janux Therapeutics Inc
JANX
ISIN US47103J1051 / Valor 111742522
Janux Therapeutics Inc
UMushroom community rating:
About company
Janux Therapeutics Inc., founded in 2017, is a biotechnology company focused on developing innovative immunotherapies for cancer treatment. The company leverages its proprietary technology to create next-generation T cell engagers designed to target and eliminate cancer cells while minimizing damage to healthy tissues. Janux successfully completed its initial public offering (IPO) in June 2021 and advanced its first therapeutic program to clinical trials in the latter half of 2022. The company's approach emphasizes a collaborative and data-driven culture to foster scientific innovation and accelerate the development of its therapeutic pipeline.
Summarized from source with an LLMView SourceSector: HealthcareKey figures
Performance
Volatility
2525 M
Market cap (USD)
158,064
Daily traded volume (Shares)
49.02 / 47.04
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
